Ryan Maynard
2023
In 2023, Ryan Maynard earned a total compensation of $1.2M as Chief Financial Officer at Cara Therapeutics, a 34% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $181,792 |
|---|---|
| Option Awards | $573,156 |
| Salary | $478,400 |
| Other | $10,509 |
| Total | $1,243,857 |
Maynard received $573.2K in option awards, accounting for 46% of the total pay in 2023.
Maynard also received $181.8K in non-equity incentive plan, $478.4K in salary and $10.5K in other compensation.
Rankings
In 2023, Ryan Maynard's compensation ranked 963rd out of 2,907 executives tracked by ExecPay. In other words, Maynard earned more than 66.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 963 out of 2,907 | 67th |
Division Manufacturing | 575 out of 1,599 | 64th |
Major group Chemicals And Allied Products | 393 out of 901 | 56th |
Industry group Drugs | 382 out of 864 | 56th |
Industry Pharmaceutical Preparations | 259 out of 622 | 58th |
Source: SEC filing on April 22, 2024.
Maynard's colleagues
We found two more compensation records of executives who worked with Ryan Maynard at Cara Therapeutics in 2023.